SVF Endurance (Cayman) Ltd 4
4 · Vir Biotechnology, Inc. · Filed Oct 17, 2019
Insider Transaction Report
Form 4
SVF Endurance (Cayman) Ltd
10% Owner
Transactions
- Conversion
Series B Convertible Preferred Stock
2019-10-16−6,111,111→ 0 total(indirect: See footnote)→ Common Stock (6,111,111 underlying) - Conversion
Common Stock, par value $0.0001 per share
2019-10-16+21,666,666→ 21,666,666 total(indirect: See footnote) - Purchase
Common Stock, par value $0.0001 per share
2019-10-16$20.00/sh+950,000$19,000,000→ 22,616,666 total(indirect: See footnote) - Conversion
Series A-1 Convertible Preferred Stock
2019-10-16−15,555,555→ 0 total(indirect: See footnote)→ Common Stock (15,555,555 underlying)
Footnotes (3)
- [F1]The Series A-1 Convertible Preferred Stock and the Series B Convertible Preferred Stock each converted into Vir Biotechnology, Inc. common stock on a one-to-one basis and had no expiration date.
- [F2]Represents securities held directly by SVF Endurance (Cayman) Limited. SVF Endurance (Cayman) Limited is a wholly-owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.
- [F3](continued from footnote 2) SBIA UK is wholly owned by SoftBank Group Corp. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission that any reporting person is the beneficial owner of such shares for purposes of the Securities Exchange Act of 1934 or for any other purpose.